Contrast-enhanced ultrasound diagnoses small renal lesions
Solid renal parenchymal lesions with a diameter of 5 cm or less can be difficult to diagnose, requiring irradiation and biopsy. Catching renal cell carcinoma in early stages before tumors grow larger than 7 cm, however, increases a patient’s chances of survival over five years. Researchers in China have found that contrast-enhanced ultrasound can accurately diagnose these small lesions.
Solid renal parenchymal lesions with a diameter of 5 cm or less can be difficult to diagnose, requiring irradiation and biopsy. Catching renal cell carcinoma in early stages before tumors grow larger than 7 cm, however, increases a patient's chances of survival over five years. Researchers in China have found that contrast-enhanced ultrasound can accurately diagnose these small lesions.
Dr. Li Fan and colleagues in the ultrasound department at the Shanghai Jiaotong University Affiliated First People's Hospital studied 71 patients with a total of 72 solid renal parenchymal lesions with a maximum diameter of 5 cm. They published their findings in the June issue of the Journal of Ultrasound in Medicine.
Each patient received conventional as well as contrast-enhanced ultrasound exams with a sulfur hexafluoride contrast agent and the cadence contrast pulse sequencing mode. Three observers blinded to the final diagnoses of the lesions reviewed these exams, and their conclusions were compared with results from definitive exams.
Ultimately, 44 of the solid renal parenchymal lesions were diagnosed as renal cell carcinomas, confirmed with pathologic exams. There were 24 renal angiomyolipomas, two hypertrophied columns of Bertin, one oncocytoma, and one renal abscess. All of these diagnoses were confirmed with pathologic, CT, MRI, and follow-up exams.
The researchers found that hypertrophied columns of Bertin were easily diagnosed using contrast-enhanced ultrasound. Renal angiomyolipomas were usually homogeneously enhanced with hypoenhancement in the arterial and late phases.
Renal cell carcinomas were best identified with hyperenhancement in the late phase, 30 to 90 seconds after the contrast agent was injected. This technique was 96.4% specific and 77.3% sensitive. Heterogeneous enhancement of the lesion also suggested renal cell carcinoma.
Some benign lesions did appear similar to hypovascular renal cell carcinomas, but with the high sensitivity and specificity of contrast-enhanced ultrasound, the researchers concluded it could be a useful test for diagnosing small solid renal parenchymal lesions.
FDA Clears Ultrasound AI Detection for Pleural Effusion and Consolidation
June 18th 2025The 14th FDA-cleared AI software embedded in the Exo Iris ultrasound device reportedly enables automated detection of key pulmonary findings that may facilitate detection of pneumonia and tuberculosis in seconds.
The Reading Room: Racial and Ethnic Minorities, Cancer Screenings, and COVID-19
November 3rd 2020In this podcast episode, Dr. Shalom Kalnicki, from Montefiore and Albert Einstein College of Medicine, discusses the disparities minority patients face with cancer screenings and what can be done to increase access during the pandemic.
Ultrasound-Guided Thermal Ablation Shows Low Recurrence of Thyroid Carcinoma at Five Years
June 16th 2025In a meta-analysis involving over 2,200 patients with T1NoMo papillary thyroid carcinoma, researchers noted 2 percent recurrence and no cases of lymph node metastasis five years after ultrasound-guided thermal ablation.
